Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 2, 2026, 5:47 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1417–1440 of 16,127 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Skin Disorder Clear all
Recruiting No phase listed Observational

Evaluating the Durability of Closure for Diabetic Foot Ulcers Following a Randomized, Controlled, Modified Platform Trial.

NCT07360418
View directory record Official record
Conditions
Diabetic Foot Ulcers (DFU), Foot Ulcer Chronic, Ulcer, Diabetic Foot Ulcer
Interventions
Blue Drop Foot Scanner
Other
Lead sponsor
Applied Biologics, LLC
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Timeline
2025 – 2027
U.S. locations
1
States / cities
Clinton Township, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Nov 2, 2026, 5:47 PM EST
Terminated Phase 2 Interventional Results available

Efficacy and Safety of Orally Administered DS107 in Adult Patients With Moderate to Severe Atopic Dermatitis

NCT03817190
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
DS107, Placebo
Drug
Lead sponsor
DS Biopharma
Industry
Eligibility
18 Years and older
Enrollment
219 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
26
States / cities
Birmingham, Alabama • Huntington Beach, California • Los Angeles, California + 22 more
Source: ClinicalTrials.gov public record
Updated Nov 28, 2022 · Synced Nov 2, 2026, 5:47 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Single Doses and Multiple Doses of BIIB059 (Litifilimab) in Healthy Volunteers and Participants With Systemic Lupus Erythematosus

NCT02106897
View directory record Official record
Conditions
Systemic Lupus Erythematosus, Healthy Volunteers
Interventions
BIIB059 (litifilimab), Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
109 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
5
States / cities
Anniston, Alabama • Birmingham, Alabama • Orlando, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2023 · Synced Nov 2, 2026, 5:47 PM EST
Not listed Phase 1 Interventional

Perillyl Alcohol in Preventing Recurrent Breast Cancer in Women Who Have Been Treated With Surgery With or Without Adjuvant Therapy

NCT00022425
View directory record Official record
Conditions
Breast Cancer
Interventions
perillyl alcohol
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 18, 2013 · Synced Nov 2, 2026, 5:47 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Single Oral Dose Study of ASP015K in Healthy Volunteers Assessing the Relative Bioavailability Across Three Tablet Strengths From a New Formulation of ASP015K

NCT01486017
View directory record Official record
Conditions
Bioavailability of ASP015K, Pharmacokinetics of ASP015K, Healthy Subjects
Interventions
ASP015K
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 6, 2011 · Synced Nov 2, 2026, 5:47 PM EST
Completed Phase 3 Interventional Results available

A Study of Trastuzumab Emtansine in Comparison With Treatment of Physician's Choice in Participants With HER2-positive Breast Cancer Who Have Received at Least Two Prior Regimens of HER2-directed Therapy

NCT01419197
View directory record Official record
Conditions
Breast Cancer
Interventions
Trastuzumab emtansine, Treatment of physician's choice
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
602 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
59
States / cities
Tucson, Arizona • Hot Springs, Arkansas • Hayward, California + 52 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2016 · Synced Nov 2, 2026, 5:47 PM EST
Completed Phase 3 Interventional Results available

Efficacy and Safety of Tralokinumab Administered by an Autoinjector in Adults and Adolescents With Moderate to Severe Atopic Dermatitis (INJECZTRA)

NCT05194540
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Tralokinumab
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
12 Years and older
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
29
States / cities
Birmingham, Alabama • Fort Smith, Arkansas • Fountain Valley, California + 24 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2025 · Synced Nov 2, 2026, 5:47 PM EST
Completed Phase 1 Interventional Results available

PH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced Melanoma

NCT01621490
View directory record Official record
Conditions
Advanced Melanoma, Metastatic Melanoma
Interventions
Nivolumab, Ipilimumab
Biological · Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
12
States / cities
Los Angeles, California • Chicago, Illinois • Lutherville, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2024 · Synced Nov 2, 2026, 5:47 PM EST
Completed Phase 2 Interventional Results available

Phase II Study of KW2871 Combined With High Dose Interferon-α2b in Patients With Metastatic Melanoma

NCT00679289
View directory record Official record
Conditions
Metastatic Melanoma, Cutaneous Melanoma
Interventions
HDI, KW2871
Drug
Lead sponsor
Ludwig Institute for Cancer Research
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
2
States / cities
Chicago, Illinois • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 12, 2022 · Synced Nov 2, 2026, 5:47 PM EST
Active, not recruiting Phase 2 Interventional

Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)

NCT05270668
View directory record Official record
Conditions
Diffuse Cutaneous Systemic Sclerosis, Interstitial Lung Disease
Interventions
Tulisokibart, Companion diagnostic ( CDx), Placebo
Drug · Diagnostic Test
Lead sponsor
Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
20
States / cities
Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 14 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Nov 2, 2026, 5:47 PM EST
Not listed Phase 2 Interventional

Treatment of Hypopigmented Scars With Bimatoprost

NCT06122090
View directory record Official record
Conditions
Scars, Hypopigmented Scar, Hypopigmented Skin, Burn Scar, Scarring, Cicatrix, Hypertrophic, Cicatrix, Pigmentation Disorder, Burns Laser
Interventions
Bimatoprost, Saline
Drug
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated May 3, 2024 · Synced Nov 2, 2026, 5:47 PM EST
Recruiting Phase 2 Interventional

Neoadjuvant INBRX-106 in Combination With Pembrolizumab for Stage II/III TNBC Patients

NCT06353997
View directory record Official record
Conditions
Triple Negative Breast Cancer
Interventions
Pembrolizumab, INBRX-106
Drug
Lead sponsor
Providence Health & Services
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
3
States / cities
Los Angeles, California • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Nov 2, 2026, 5:47 PM EST
Not listed Phase 1 Interventional

Cardiac Safety Assessment Study of Picoplatin in Solid Tumors

NCT00710697
View directory record Official record
Conditions
Solid Tumors
Interventions
Picoplatin
Drug
Lead sponsor
Poniard Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
7
States / cities
Scottsdale, Arizona • La Jolla, California • Santa Monica, California + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2009 · Synced Nov 2, 2026, 5:47 PM EST
Completed Not applicable Interventional

Pain, Psychological, and Endocannabinoid Responses to Yoga in Breast Cancer Survivors With Chemotherapy-induced Neuropathic Pain

NCT04075097
View directory record Official record
Conditions
Breast Cancer, Chemotherapy-induced Peripheral Neuropathy, Neuropathic Pain
Interventions
Aerobic exercise, Iyengar yoga
Behavioral
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older · Female only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 20, 2020 · Synced Nov 2, 2026, 5:47 PM EST
Completed Phase 2 Interventional Results available

Peptide Vaccination for Patients at High Risk for Recurrent Melanoma

NCT00059475
View directory record Official record
Conditions
Melanoma
Interventions
Glycoprotein 100 (GP100): 209-217 (210M), Interleukin-2 (IL-2), Montanide ISA 51, Melanoma antigen recognized by T-cells (MART)-1: 27-35, 27-35 (27L): melanoma antigen recognized by T-cells (MART)-1, melanoma antigen recognized by T-cells (MART)-1: 26-35(27L)
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
7 Years and older
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 23, 2012 · Synced Nov 2, 2026, 5:47 PM EST
Completed Phase 2 Interventional

Tretinoin With or Without Fenretinide in Treating Patients With Dysplastic Nevus Syndrome

NCT00003601
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
fenretinide, tretinoin
Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years to 120 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2004
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 18, 2023 · Synced Nov 2, 2026, 5:47 PM EST
Terminated Not applicable Interventional Accepts healthy volunteers

Assessing the Sensitivity of "SureTouch™" in Women Undergoing Diagnostic and Screening Mammography

NCT04397029
View directory record Official record
Conditions
Breast Cancer
Interventions
SureTouch
Device
Lead sponsor
George Washington University
Other
Eligibility
30 Years to 80 Years · Female only
Enrollment
213 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jun 13, 2022 · Synced Nov 2, 2026, 5:47 PM EST
Completed Not applicable Interventional

Clinical Study Evaluating the Safety and Effectiveness of the NIRA Laser M2.1 for the Treatment of Full-Face Wrinkles

NCT07572331
View directory record Official record
Conditions
Skin Ageing, Facial Wrinkles, Acne, Skin Elasticity, Infraorbital Dark Circle Severity, Skin Firmness, UV Spots, Skin Texture, Skin Pores, Brown Spots, Porphyrins, Red Spots
Interventions
NIRA Laser M2.1, Topical
Device · Other
Lead sponsor
NIRA Innovations Inc.
Industry
Eligibility
35 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Beverly, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Nov 2, 2026, 5:47 PM EST
Completed Phase 2 Interventional Results available

Evaluation of Sonelokimab for the Treatment of Patients With Active Psoriatic Arthritis

NCT05640245
View directory record Official record
Conditions
Arthritis, Psoriatic
Interventions
Sonelokimab, Placebo, Adalimumab
Drug
Lead sponsor
MoonLake Immunotherapeutics AG
Industry
Eligibility
18 Years and older
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
2
States / cities
Rancho Mirage, California • Duncansville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Nov 2, 2026, 5:47 PM EST
Withdrawn Phase 2 Interventional

Low-Dose Conditioning Followed by Donor Stem Cell Transplant in Treating Patients With Severe Systemic Sclerosis

NCT01047072
View directory record Official record
Conditions
Systemic Scleroderma
Interventions
fludarabine phosphate, total-body irradiation, tacrolimus, mycophenolate mofetil, rituximab, cyclophosphamide, nonmyeloablative allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation
Drug · Radiation · Biological + 1 more
Lead sponsor
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 31, 2012 · Synced Nov 2, 2026, 5:47 PM EST
Completed Phase 1Phase 2 Interventional

Study of PI-88 in Patients With Advanced Melanoma

NCT00068172
View directory record Official record
Conditions
Melanoma
Interventions
PI-88
Drug
Lead sponsor
Cellxpert Biotechnology Corp.
Industry
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2007
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 27, 2022 · Synced Nov 2, 2026, 5:47 PM EST
Withdrawn Not applicable Interventional

Response of Urticaria to Stress Intervention

NCT01047137
View directory record Official record
Conditions
Chronic Urticaria
Interventions
Psychological Stress Intervention, General Supportive Therapy
Behavioral
Lead sponsor
University of Mississippi Medical Center
Other
Eligibility
18 Years to 64 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated Feb 20, 2018 · Synced Nov 2, 2026, 5:47 PM EST
Not listed Phase 2 Interventional

Tavo and Pembrolizumab in Patients With Stage III/IV Melanoma Progressing on Either Pembrolizumab or Nivolumab Treatment

NCT03132675
View directory record Official record
Conditions
Stage III/IV Melanoma
Interventions
tavokinogene telseplasmid, Pembrolizumab, ImmunoPulse
Biological · Device
Lead sponsor
OncoSec Medical Incorporated
Industry
Eligibility
18 Years and older
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
23
States / cities
Tucson, Arizona • Yuma, Arizona • La Jolla, California + 20 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2023 · Synced Nov 2, 2026, 5:47 PM EST
Recruiting Not applicable Interventional

Intervention to Improve Communication and Medication Adherence in Lupus

NCT06458075
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
CO-LEAD
Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years to 90 Years
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Nov 2, 2026, 5:47 PM EST